VERSARTIS, INC. (NASDAQ:VSAR) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

VERSARTIS, INC. (NASDAQ:VSAR) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Story continues below

Item5.03.

Amendments to the Articles of Incorporation or
Bylaws

At the Annual Meeting (as defined in Item5.07), as discussed in
Item5.07 (Proposal 2) in this Current Report on Form 8-K, the
stockholders of Versartis, Inc. (the Company) approved an
amendment to the Companys Amended and Restated Certificate of
Incorporation (the Amendment) to increase the authorized number
of shares of common stock, par value $0.0001 (Common Stock), the
Company may issue from 50,000,000 shares to 100,000,000 shares.
The Amendment became effective on May31, 2017, upon filing of a
certificate of amendment with the Secretary of State of the State
of Delaware.

The foregoing description of the amendment does not purport to be
complete and is qualified in its entirety by reference to the
full text of the Certificate of Amendment to the Amended and
Restated Certificate of Incorporation of Versartis, Inc.,
attached as Exhibit 3.1 to this Current Report on Form 8-K and is
incorporated herein by reference.

Item5.07. Submission of Matters to a Vote of Security
Holders

On May25, 2017, the Company held its Annual Meeting of
Stockholders at 2:00 p.m. local time via live audio webcast (the
Annual Meeting). As of April4, 2017, the Companys record date,
there were a total of 35,162,043 shares of Common Stock
outstanding and entitled to vote at the Annual Meeting. At the
Annual Meeting, 25,585,129 shares of Common Stock were
represented by online ballot or by proxy and, therefore, a quorum
was present. Three items of business were acted upon by the
stockholders at the Annual Meeting. The final results for the
votes regarding each proposal are set forth below.

Proposal 1Election of Directors to Hold Office Until the
2020 Annual Meeting of Stockholders

Dr.Srini Akkaraju, John Varian and Eric L. Dobmeier were elected
to serve as members of the Companys Board of Directors (the
Board) for three-year terms and until their respective successors
shall be elected and qualified or until their earlier resignation
or removal.

Votes were cast as follows for the election of directors:

For Withheld BrokerNon-Votes

Dr. Srini Akkaraju

19,248,518 2,004,337 4,332,274

John Varian

19,759,352 1,493,503 4,332,274

Eric L. Dobmeier

18,418,032 2,834,823 4,332,274

Since the Board is divided into three classes with one class
elected each year to hold office for a three-year term, the
following directors continued to serve as directors of the
Company immediately after the Annual Meeting: Jay P. Shepard, R.
Scott Greer, Edmon R. Jennings, Dr.Shahzad Malik, Dr.AnthonyY.
Sun.

Proposal 2Approval of Amendment to the Companys Amended
and Restated Certificate of Incorporation

The stockholders approved an amendment to the Companys Amended
and Restated Certificate of incorporation increasing the number
of authorized shares of common stock the Company may issue from
50,000,000 to 100,000,000 shares by the following vote:

For

Against

Abstain

BrokerNon-Votes

20,732,202

4,678,085 174,842

Proposal 3Ratification of the Selection of the
Independent Registered Public Accounting Firm

The stockholders ratified the selection of PricewaterhouseCoopers
LLP as the Companys independent registered public accounting firm
for the year ending December31, 2017 by the following vote:

For

Against

Abstain

BrokerNon-Votes

25,464,991

119,590
Item9.01. Financial Statements and Exhibits.
(d) Exhibits

Number

Description

3.1 Certificate of Amendment to Amended and Restated Certificate
of Incorporation of Versartis, Inc.


About VERSARTIS, INC. (NASDAQ:VSAR)

Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology. The Company’s VRS-317 combines the rhGH amino acid sequence utilized in approved rhGH products with a half-life extension technology, XTEN, to enable less frequent administration. The XTEN technology consists of hydrophilic amino acids added at the genetic level as part of the manufacturing process. The Company’s XTEN is a recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins in a tunable manner. The XTEN sequence consists of hydrophilic amino acids and possesses various additional properties, which are used for the development of protein pharmaceuticals.

VERSARTIS, INC. (NASDAQ:VSAR) Recent Trading Information

VERSARTIS, INC. (NASDAQ:VSAR) closed its last trading session up +1.00 at 16.35 with 190,364 shares trading hands.

An ad to help with our costs